Replies to post #151236 on Biotech Values

[zipjet]

3Q12 US Tysabri sales were $230M, +17% YoY, +9% QoQ:

9% sequential is very good, provided there is not a price increase in that.

The delay of BG12 to the end of March will also delay switching.

ij

[DewDiligence]

4Q12 US Tysabri sales were $243M, +24% YoY and +6% QoQ:

http://finance.yahoo.com/news/biogen-idec-2012-revenue-increases-113000720.html